International Triadin Knockout Syndrome Registry

Daniel J. Clemens, David J. Tester, John R. Giudicessi, J. Martijn Bos, Ram K. Rohatgi, Dominic J. Abrams, Seshadri Balaji, Lia Crotti, Julien Faure, Carlo Napolitano, Silvia G. Priori, Vincent Probst, Caroline Rooryck-Thambo, Nathalie Roux-Buisson, Frederic Sacher, Peter J. Schwartz, Michael J. Silka, Mark A. Walsh, Michael John Ackerman

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

BACKGROUND: Triadin knockout syndrome (TKOS) is a rare, inherited arrhythmia syndrome caused by recessive null mutations in TRDN-encoded cardiac triadin. Based previously on 5 triadin null patients, TKOS has been characterized by extensive T-wave inversions, transient QT prolongation, and severe disease expression of exercise-induced cardiac arrest in early childhood refractory to conventional therapy. METHODS: We have established the International Triadin Knockout Syndrome Registry to include patients who have genetically proven homozygous/compound heterozygous TRDN null mutations. Clinical/genetic data were collected using an online survey generated through REDCap. RESULTS: Currently, the International Triadin Knockout Syndrome Registry includes 21 patients (11 males, average age of 18 years) from 16 families. Twenty patients (95%) presented with either cardiac arrest (15, 71%) or syncope (5, 24%) at an average age of 3 years. Mild skeletal myopathy/proximal muscle weakness was noted in 6 (29%) patients. Of the 19 surviving patients, 16 (84%) exhibit T-wave inversions, and 10 (53%) have transient QT prolongation > 480 ms. Eight of 9 patients had ventricular ectopy on exercise stress testing. Thirteen (68%) patients have received implantable defibrillators. Despite various treatment strategies, 14 (74%) patients have had recurrent breakthrough cardiac events. CONCLUSION: TKOS is a potentially lethal disease characterized by T-wave inversions in the precordial leads, transient QT prolongation in some, and recurrent ventricular arrhythmias at a young age despite aggressive treatment. Patients displaying this phenotype should undergo TRDN genetic testing as TKOS may be a cause for otherwise unexplained cardiac arrest in young children. As gene therapy advances, enrollment into the International Triadin Knockout Syndrome Registry is encouraged to better understand TKOS and to ready a well-characterized cohort for future TRDN gene therapy trials.

Original languageEnglish (US)
Pages (from-to)e002419
JournalCirculation. Genomic and precision medicine
Volume12
Issue number2
DOIs
StatePublished - Feb 1 2019

Fingerprint

Registries
Heart Arrest
Genetic Therapy
Cardiac Arrhythmias
triadin
Exercise
Induced Heart Arrest
Mutation
Implantable Defibrillators
Muscle Weakness
Syncope
Genetic Testing
Muscular Diseases
Therapeutics
Phenotype

Keywords

  • genetics
  • human
  • long QT syndrome
  • pediatrics
  • phenotype

Cite this

Clemens, D. J., Tester, D. J., Giudicessi, J. R., Bos, J. M., Rohatgi, R. K., Abrams, D. J., ... Ackerman, M. J. (2019). International Triadin Knockout Syndrome Registry. Circulation. Genomic and precision medicine, 12(2), e002419. https://doi.org/10.1161/CIRCGEN.118.002419

International Triadin Knockout Syndrome Registry. / Clemens, Daniel J.; Tester, David J.; Giudicessi, John R.; Bos, J. Martijn; Rohatgi, Ram K.; Abrams, Dominic J.; Balaji, Seshadri; Crotti, Lia; Faure, Julien; Napolitano, Carlo; Priori, Silvia G.; Probst, Vincent; Rooryck-Thambo, Caroline; Roux-Buisson, Nathalie; Sacher, Frederic; Schwartz, Peter J.; Silka, Michael J.; Walsh, Mark A.; Ackerman, Michael John.

In: Circulation. Genomic and precision medicine, Vol. 12, No. 2, 01.02.2019, p. e002419.

Research output: Contribution to journalArticle

Clemens, DJ, Tester, DJ, Giudicessi, JR, Bos, JM, Rohatgi, RK, Abrams, DJ, Balaji, S, Crotti, L, Faure, J, Napolitano, C, Priori, SG, Probst, V, Rooryck-Thambo, C, Roux-Buisson, N, Sacher, F, Schwartz, PJ, Silka, MJ, Walsh, MA & Ackerman, MJ 2019, 'International Triadin Knockout Syndrome Registry', Circulation. Genomic and precision medicine, vol. 12, no. 2, pp. e002419. https://doi.org/10.1161/CIRCGEN.118.002419
Clemens DJ, Tester DJ, Giudicessi JR, Bos JM, Rohatgi RK, Abrams DJ et al. International Triadin Knockout Syndrome Registry. Circulation. Genomic and precision medicine. 2019 Feb 1;12(2):e002419. https://doi.org/10.1161/CIRCGEN.118.002419
Clemens, Daniel J. ; Tester, David J. ; Giudicessi, John R. ; Bos, J. Martijn ; Rohatgi, Ram K. ; Abrams, Dominic J. ; Balaji, Seshadri ; Crotti, Lia ; Faure, Julien ; Napolitano, Carlo ; Priori, Silvia G. ; Probst, Vincent ; Rooryck-Thambo, Caroline ; Roux-Buisson, Nathalie ; Sacher, Frederic ; Schwartz, Peter J. ; Silka, Michael J. ; Walsh, Mark A. ; Ackerman, Michael John. / International Triadin Knockout Syndrome Registry. In: Circulation. Genomic and precision medicine. 2019 ; Vol. 12, No. 2. pp. e002419.
@article{8e66208055384ef18e2bdccb58e18ab2,
title = "International Triadin Knockout Syndrome Registry",
abstract = "BACKGROUND: Triadin knockout syndrome (TKOS) is a rare, inherited arrhythmia syndrome caused by recessive null mutations in TRDN-encoded cardiac triadin. Based previously on 5 triadin null patients, TKOS has been characterized by extensive T-wave inversions, transient QT prolongation, and severe disease expression of exercise-induced cardiac arrest in early childhood refractory to conventional therapy. METHODS: We have established the International Triadin Knockout Syndrome Registry to include patients who have genetically proven homozygous/compound heterozygous TRDN null mutations. Clinical/genetic data were collected using an online survey generated through REDCap. RESULTS: Currently, the International Triadin Knockout Syndrome Registry includes 21 patients (11 males, average age of 18 years) from 16 families. Twenty patients (95{\%}) presented with either cardiac arrest (15, 71{\%}) or syncope (5, 24{\%}) at an average age of 3 years. Mild skeletal myopathy/proximal muscle weakness was noted in 6 (29{\%}) patients. Of the 19 surviving patients, 16 (84{\%}) exhibit T-wave inversions, and 10 (53{\%}) have transient QT prolongation > 480 ms. Eight of 9 patients had ventricular ectopy on exercise stress testing. Thirteen (68{\%}) patients have received implantable defibrillators. Despite various treatment strategies, 14 (74{\%}) patients have had recurrent breakthrough cardiac events. CONCLUSION: TKOS is a potentially lethal disease characterized by T-wave inversions in the precordial leads, transient QT prolongation in some, and recurrent ventricular arrhythmias at a young age despite aggressive treatment. Patients displaying this phenotype should undergo TRDN genetic testing as TKOS may be a cause for otherwise unexplained cardiac arrest in young children. As gene therapy advances, enrollment into the International Triadin Knockout Syndrome Registry is encouraged to better understand TKOS and to ready a well-characterized cohort for future TRDN gene therapy trials.",
keywords = "genetics, human, long QT syndrome, pediatrics, phenotype",
author = "Clemens, {Daniel J.} and Tester, {David J.} and Giudicessi, {John R.} and Bos, {J. Martijn} and Rohatgi, {Ram K.} and Abrams, {Dominic J.} and Seshadri Balaji and Lia Crotti and Julien Faure and Carlo Napolitano and Priori, {Silvia G.} and Vincent Probst and Caroline Rooryck-Thambo and Nathalie Roux-Buisson and Frederic Sacher and Schwartz, {Peter J.} and Silka, {Michael J.} and Walsh, {Mark A.} and Ackerman, {Michael John}",
year = "2019",
month = "2",
day = "1",
doi = "10.1161/CIRCGEN.118.002419",
language = "English (US)",
volume = "12",
pages = "e002419",
journal = "Circulation. Genomic and precision medicine",
issn = "1942-325X",
publisher = "Lippincott Williams and Wilkins Ltd.",
number = "2",

}

TY - JOUR

T1 - International Triadin Knockout Syndrome Registry

AU - Clemens, Daniel J.

AU - Tester, David J.

AU - Giudicessi, John R.

AU - Bos, J. Martijn

AU - Rohatgi, Ram K.

AU - Abrams, Dominic J.

AU - Balaji, Seshadri

AU - Crotti, Lia

AU - Faure, Julien

AU - Napolitano, Carlo

AU - Priori, Silvia G.

AU - Probst, Vincent

AU - Rooryck-Thambo, Caroline

AU - Roux-Buisson, Nathalie

AU - Sacher, Frederic

AU - Schwartz, Peter J.

AU - Silka, Michael J.

AU - Walsh, Mark A.

AU - Ackerman, Michael John

PY - 2019/2/1

Y1 - 2019/2/1

N2 - BACKGROUND: Triadin knockout syndrome (TKOS) is a rare, inherited arrhythmia syndrome caused by recessive null mutations in TRDN-encoded cardiac triadin. Based previously on 5 triadin null patients, TKOS has been characterized by extensive T-wave inversions, transient QT prolongation, and severe disease expression of exercise-induced cardiac arrest in early childhood refractory to conventional therapy. METHODS: We have established the International Triadin Knockout Syndrome Registry to include patients who have genetically proven homozygous/compound heterozygous TRDN null mutations. Clinical/genetic data were collected using an online survey generated through REDCap. RESULTS: Currently, the International Triadin Knockout Syndrome Registry includes 21 patients (11 males, average age of 18 years) from 16 families. Twenty patients (95%) presented with either cardiac arrest (15, 71%) or syncope (5, 24%) at an average age of 3 years. Mild skeletal myopathy/proximal muscle weakness was noted in 6 (29%) patients. Of the 19 surviving patients, 16 (84%) exhibit T-wave inversions, and 10 (53%) have transient QT prolongation > 480 ms. Eight of 9 patients had ventricular ectopy on exercise stress testing. Thirteen (68%) patients have received implantable defibrillators. Despite various treatment strategies, 14 (74%) patients have had recurrent breakthrough cardiac events. CONCLUSION: TKOS is a potentially lethal disease characterized by T-wave inversions in the precordial leads, transient QT prolongation in some, and recurrent ventricular arrhythmias at a young age despite aggressive treatment. Patients displaying this phenotype should undergo TRDN genetic testing as TKOS may be a cause for otherwise unexplained cardiac arrest in young children. As gene therapy advances, enrollment into the International Triadin Knockout Syndrome Registry is encouraged to better understand TKOS and to ready a well-characterized cohort for future TRDN gene therapy trials.

AB - BACKGROUND: Triadin knockout syndrome (TKOS) is a rare, inherited arrhythmia syndrome caused by recessive null mutations in TRDN-encoded cardiac triadin. Based previously on 5 triadin null patients, TKOS has been characterized by extensive T-wave inversions, transient QT prolongation, and severe disease expression of exercise-induced cardiac arrest in early childhood refractory to conventional therapy. METHODS: We have established the International Triadin Knockout Syndrome Registry to include patients who have genetically proven homozygous/compound heterozygous TRDN null mutations. Clinical/genetic data were collected using an online survey generated through REDCap. RESULTS: Currently, the International Triadin Knockout Syndrome Registry includes 21 patients (11 males, average age of 18 years) from 16 families. Twenty patients (95%) presented with either cardiac arrest (15, 71%) or syncope (5, 24%) at an average age of 3 years. Mild skeletal myopathy/proximal muscle weakness was noted in 6 (29%) patients. Of the 19 surviving patients, 16 (84%) exhibit T-wave inversions, and 10 (53%) have transient QT prolongation > 480 ms. Eight of 9 patients had ventricular ectopy on exercise stress testing. Thirteen (68%) patients have received implantable defibrillators. Despite various treatment strategies, 14 (74%) patients have had recurrent breakthrough cardiac events. CONCLUSION: TKOS is a potentially lethal disease characterized by T-wave inversions in the precordial leads, transient QT prolongation in some, and recurrent ventricular arrhythmias at a young age despite aggressive treatment. Patients displaying this phenotype should undergo TRDN genetic testing as TKOS may be a cause for otherwise unexplained cardiac arrest in young children. As gene therapy advances, enrollment into the International Triadin Knockout Syndrome Registry is encouraged to better understand TKOS and to ready a well-characterized cohort for future TRDN gene therapy trials.

KW - genetics

KW - human

KW - long QT syndrome

KW - pediatrics

KW - phenotype

UR - http://www.scopus.com/inward/record.url?scp=85061859306&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061859306&partnerID=8YFLogxK

U2 - 10.1161/CIRCGEN.118.002419

DO - 10.1161/CIRCGEN.118.002419

M3 - Article

C2 - 30649896

AN - SCOPUS:85061859306

VL - 12

SP - e002419

JO - Circulation. Genomic and precision medicine

JF - Circulation. Genomic and precision medicine

SN - 1942-325X

IS - 2

ER -